Showing 2642 results
- Media Release /With further follow-up of MONALEESA-3, Kisqali plus fulvestrant achieved a median overall survival (OS) of more than five-and-a-half years (67.6 months) in the first-line (1L) setting for…
- Story /
- Story /
New NIBR President Jay Bradner shares on drug discovery, his leadership style and what’s next for his career in biomedical research.
- Story /
A Cell & Gene production unit staffed by a highly trained team at Novartis will soon begin operating in Stein, Switzerland.
- Story /
A certain leggy resident of the African grasslands is arousing a lot of interest among evolutionary biologists. They believe that study of giraffes' unique features could lead the way to advances in human health.
- Media Release /Jakavi is the first JAK1/2 inhibitor available for patients in Europe who previously had no approved therapies for the treatment of steroid-refractory graft-versus-host disease (GvHD)1,2 In clinical…
- Story /
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 265
- › Next page